EGFR Status Assessment for Better Care of Early Stage Non-Small Cell Lung Carcinoma: What Is Changing in the Daily Practice of Pathologists?

The recent emergence of novel neoadjuvant and/or adjuvant therapies for early stage (I-IIIA) non-small cell lung carcinoma (NSCLC), mainly tyrosine kinase inhibitors (TKIs) targeting EGFR mutations and immunotherapy or chemo-immunotherapy, has suddenly required the evaluation of biomarkers predictiv...

Descripción completa

Detalles Bibliográficos
Autor principal: Hofman, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8392580/
https://www.ncbi.nlm.nih.gov/pubmed/34440926
http://dx.doi.org/10.3390/cells10082157

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8392580/
https://www.ncbi.nlm.nih.gov/pubmed/34440926
http://dx.doi.org/10.3390/cells10082157

Ejemplares similares